Novartis: Phase III data shows Cosentyx delivered long-lasting skin clearance
Novartis announced first of its kind Phase III data showing Cosentyx delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years. These data were presented for the first time at the 26th European Academy of Dermatology and Venereology, or EADV, Congress in Geneva, Switzerland. By specifically targeting interleukin-17A, or IL-17A, Cosentyx addresses the key cytokine involved in the development of psoriasis. IL-17A plays a significant role in the pathogenesis of plaque psoriasis, psoriatic arthritis, or PsA, and ankylosing spondylitis. Inhibiting IL-17A is important as up to 30% of patients with psoriasis may have PsA.